Clinical Trials

20 enrolled

Breast Neoplasms

NCT05765851 2026-06-05

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

108 enrolled

Breast Neoplasms

NCT05812807 2026-06-05

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Phase NA Not yet recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05874297 2026-06-05

ONE

50 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05891171 2026-06-05

ARC-25

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06058377 2026-06-05

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06214793 2026-06-05

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Phase 2 Suspended

61 enrolled

Breast Neoplasms

NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

103 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06297265 2026-06-05

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery

50 enrolled

Breast Carcinoma In Situ

NCT06377852 2026-06-05

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

500 enrolled

Breast Neoplasms

NCT06570031 2026-06-05

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1 Completed

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06876714 2026-06-05

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

1,524 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06977620 2026-06-05

Effect of CKC and WS Exercises on Postural Stability in Unilateral Post Mastectomy Lymphedema

Phase NA Completed

60 enrolled

Breast Cancer Lymphedema

NCT07007559 2026-06-05

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07383506 2026-06-05

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Phase 1 Recruiting

90 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT07391774 2026-06-05

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07604571 2026-06-05

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Phase 1 Recruiting

194 enrolled

Phase NA Not yet recruiting

Advanced HR+/HER2- Breast Cancer

NCT07629206 2026-06-05

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

400 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplasms

NCT07630103 2026-06-05

Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

100 enrolled

Advanced Breast Cancer

NCT07630402 2026-06-05

POCEB

20 enrolled

Phase 4 Not yet recruiting

Breast Cancer With Low to Intermediate HER2 Expression

NCT07630948 2026-06-05

riboADHERE

90 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Medication Adherence

NCT07630961 2026-06-05

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

66 enrolled

BreastGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07631026 2026-06-05

Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery

Phase NA Not yet recruiting

50 enrolled

Breast Neoplasms

NCT07631052 2026-06-05

Capecitabine in ER+/HER2-negative Breast Cancer

15 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT00609791 2026-06-04

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

40 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT03011684 2026-06-04

TALES

309 enrolled

Breast Neoplasms, Infertility

NCT03632941 2026-06-04

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Phase 2 Terminated

8 enrolled 13 charts

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasms

NCT03768492 2026-06-04

ReDCoAT

60 enrolled

Phase NA Active not recruiting

Breast Neoplasms

NCT03975959 2026-06-04

PROMESSE

Phase NA Completed

426 enrolled

BreastCNS

Breast Neoplasms, Glioblastoma, Glioma

NCT04180579 2026-06-04

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

34 enrolled

Alopecia, Breast Neoplasms

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04457895 2026-06-04

SKYPE2

108 enrolled

Breast Neoplasms

NCT04895709 2026-06-04

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

1,109 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05232916 2026-06-04

FLAMINGO-01

750 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05386108 2026-06-04

ELECTRA

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT05660083 2026-06-04

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

36 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05741164 2026-06-04

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Triple Negative Breast Neoplasms

NCT05768139 2026-06-04

PIKALO-1

BreastGynecologicHead & Neck

880 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05870579 2026-06-04

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

48 enrolled

Breast Neoplasms

NCT05890677 2026-06-04

LYMPH

280 enrolled

Breast Cancer Lymphedema

NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

BreastCNSGastrointestinalThoracic

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06253871 2026-06-04

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Phase 1 Recruiting

383 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Stomach Neoplasms

NCT06274515 2026-06-04

REMERGE

Phase 4 Recruiting

320 enrolled

Breast Neoplasms

NCT06351332 2026-06-04

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Phase 1 Terminated

7 enrolled